GlassScriptPhysician profile
Dawn C Roman
NPI 1831199587
$842.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $768 · 2022: $73.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $207.53 | 2021-2022 | |
| Abbvie INC. | $198.39 | 2021 | |
| Janssen Biotech, INC. | $97.79 | 2021 | |
| Vyne Pharmaceuticals INC. | $70.34 | 2021 | |
| Pfizer INC. | $56.74 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $50.01 | 2021 | |
| Amgen INC. | $37.56 | 2021 | |
| Almirall LLC | $21.51 | 2021 | |
| Lilly USA, LLC | $20.75 | 2021 | |
| Ucb, INC. | $19.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.21 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.72 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.37 | 2021 | |
| Galderma Laboratories, L.P. | $12.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.